Amgen Inc (AMGN)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 7,471,000 | 36,285,000 | 36,377,000 | 18,081,000 | 17,848,000 |
Revenue | US$ in thousands | 25,568,000 | 51,272,000 | 50,799,000 | 25,424,000 | 23,362,000 |
Gross profit margin | 29.22% | 70.77% | 71.61% | 71.12% | 76.40% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $7,471,000K ÷ $25,568,000K
= 29.22%
AMGEN Inc.'s gross profit margin has shown a declining trend over the past five years, decreasing from 81.35% in 2019 to 70.02% in 2023. This indicates a decrease in the percentage of revenue remaining after accounting for the cost of goods sold. The declining trend suggests potential challenges in managing production costs or pricing strategies. Further analysis is recommended to identify specific factors driving this decrease and to evaluate the company's overall profitability.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Amgen Inc
AMGN
29.22%
Bio-Techne Corp
TECH
66.39%
Biogen Inc
BIIB
43.65%
Gilead Sciences Inc
GILD
40.25%
Halozyme Therapeutics Inc
HALO
48.04%
Krystal Biotech Inc
KRYS
-76.46%
Moderna Inc
MRNA
-11.69%
Neurocrine Biosciences Inc
NBIX
50.57%
Regenxbio Inc
RGNX
-71.48%
Repligen Corporation
RGEN
-2.56%
Vericel Corp Ord
VCEL
68.64%